Skip to main content
Discovering the causes of cancer and the means of prevention
 

COVID-19 Seroprevalence Studies Hub (SeroHub)

COVID-19 SeroHub is designed to address questions about changes in prevalence over time, types of serology tests being utilized, and whether a specific state has an active serology study in place.

Credit: iStock

The COVID-19 Seroprevalence Studies Hub (SeroHub) was developed by epidemiologists, data scientists, data engineers and other researchers at the Centers for Disease Control and Prevention (CDC), the National Cancer Institute, and the National Institute of Allergy and Infectious Diseases (NIAID), parts of the National Institutes of Health, to compare COVID-19 seroprevalence studies across the country. 

COVID-19 SeroHub went live on December 1, 2020, with data from seroprevalence studies conducted across the U.S. by CDC, NIH, state and local health departments, universities, and other sources. Additional studies will be added as they become available. The site will systematically identify published and ongoing SARS-CoV-2 seroprevalence studies via an interactive dashboard to visualize seroprevalence estimates over time and by geography, population, and other factors. The goal is to address questions about changes in prevalence over time, types of serology tests being utilized, and whether a specific state has an active serology study in place.

For more information, contact Neal Freedman.

Explore the COVID SeroHub site.

Learn more about COVID-related research in DCEG.